Mapatumumab

Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. ❋ Unknown (2010)

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC ❋ Editors (2010)

HGS also has several drugs in earlier stages of development for treatment of cancer, led by the TRAIL receptor antibody mapatumumab and a small-molecule antagonist of inhibitor-of-apoptosis proteins. ❋ Unknown (2010)

No clinical activity of single-agent mapatumumab was observed in patients with advanced refractory CRC. ❋ T Trarbach (2010)

All patients received two loading doses of mapatumumab (20 kg − 1 every 14 days), followed by maintenance therapy with ❋ T Trarbach (2010)

However, on the basis of its favourable safety profile and pre-clinical evidence of potential synergy in combination with agents commonly used in the treatment of colorectal cancer, further evaluation of mapatumumab in combination with chemotherapy is warranted. ❋ T Trarbach (2010)

This phase II multicentre study was designed to evaluate the efficacy and safety of mapatumumab in patients with colorectal cancer (CRC) who had failed to respond to, were intolerant to, or not candidates for fluoropyrimidine, oxaliplatin, and irinotecan-based regimens. ❋ T Trarbach (2010)

The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody mapatumumab and a small-molecule antagonist of inhibitor-of-apoptosis proteins (IAP's). ❋ Unknown (2009)

"We are pleased to initiate this first human study of HGS1029 in lymphoid malignancies, and we look forward to continuing the study of our IAP inhibitors both alone and in combination with other anti-cancer agents, including mapatumumab, our agonistic antibody to TRAIL receptor 1," said Gilles Gallant, B. Pharm., ❋ Unknown (2009)

"We are pleased to initiate this first human study of HGS1029 in lymphoid malignancies, and we look forward to continuing the study of our IAP inhibitors both alone and in combination with other anti-cancer agents, including mapatumumab, our agonistic antibody to TRAIL receptor ❋ Unknown (2009)